Search Results
2021 West Oncology | Lung Cancer | EGFR Mutation Therapy Resistance and ADCs and TROP2
JIN-A02: a highly effective 4th generation EGFR-TKI, targeting EGFR C797S triple mutation in NSCLC
2021 West Oncology | Lung Cancer | Targeted Therapies
2021 West Oncology APP | Lung Cancer Treatments Update
Are You Prepared for the New Wave of ADCs in NSCLC? Targeting HER2, HER3, TROP2, and Others
Dr. Zhu on Primary Resistance to Osimertinib in EGFR-Mutant NSCLC
Reshaping the Future of Lung Cancer Treatment With TROP2-Targeting ADCs and Rational Combinations
Osimertinib for EGFR T790M Resistance Mutations in NSCLC
Activity of EGFR TKIs in patients with NSCLC with uncommon EGFR mutations
EGFR Initial Treatment, Acquired Resistance and Q&A with H. Jack West, MD and Helena Yu, MD
GRACE Targeted Therapies Lung Cancer 2021 - Management of Uncommon EGFR Mutations Including EXON 20
2021 West Oncology | Breast Cancer | New Advances for Metastatic TNBC
